30,262 Shares in Organon & Co. (NYSE:OGN) Purchased by Prevail Innovative Wealth Advisors LLC

Prevail Innovative Wealth Advisors LLC acquired a new position in Organon & Co. (NYSE:OGN - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,262 shares of the company's stock, valued at approximately $451,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Millstone Evans Group LLC bought a new position in Organon & Co. during the fourth quarter worth $29,000. GeoWealth Management LLC bought a new position in Organon & Co. during the fourth quarter worth $41,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Organon & Co. in the 1st quarter valued at $60,000. Jones Financial Companies Lllp increased its holdings in Organon & Co. by 1,795.8% in the 4th quarter. Jones Financial Companies Lllp now owns 4,550 shares of the company's stock valued at $68,000 after buying an additional 4,310 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Organon & Co. by 186.9% in the 1st quarter. GAMMA Investing LLC now owns 4,611 shares of the company's stock valued at $69,000 after buying an additional 3,004 shares during the period. Institutional investors own 77.43% of the company's stock.

Analyst Ratings Changes

OGN has been the topic of several analyst reports. Morgan Stanley lowered their price target on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Piper Sandler lowered their price target on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Evercore ISI lowered shares of Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. Finally, BNP Paribas raised shares of Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $18.00.

Organon & Co. Price Performance

Shares of OGN traded down $0.12 during trading hours on Friday, hitting $9.53. The stock had a trading volume of 501,461 shares, compared to its average volume of 3,597,569. The company's fifty day moving average is $9.51 and its two-hundred day moving average is $12.57. The company has a debt-to-equity ratio of 16.49, a current ratio of 1.67 and a quick ratio of 1.15. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $23.10. The stock has a market capitalization of $2.48 billion, a price-to-earnings ratio of 3.31, a P/E/G ratio of 1.00 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.13. Organon & Co. had a net margin of 11.92% and a return on equity of 227.43%. The business had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the prior year, the firm earned $1.22 EPS. The firm's quarterly revenue was down 6.7% compared to the same quarter last year. On average, analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Stockholders of record on Monday, May 12th were issued a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.84%. The ex-dividend date was Monday, May 12th. Organon & Co.'s payout ratio is 2.78%.

Insider Activity

In other news, insider Kirke Weaver bought 8,045 shares of the stock in a transaction dated Tuesday, May 6th. The shares were acquired at an average price of $9.21 per share, with a total value of $74,094.45. Following the acquisition, the insider owned 52,489 shares in the company, valued at $483,423.69. This trade represents a 18.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin Ali bought 34,000 shares of the stock in a transaction dated Monday, May 5th. The stock was purchased at an average cost of $8.80 per share, for a total transaction of $299,200.00. Following the acquisition, the chief executive officer owned 282,731 shares in the company, valued at $2,488,032.80. The trade was a 13.67% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 102,345 shares of company stock worth $902,430 in the last quarter. 1.96% of the stock is owned by company insiders.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.